Be Careful of new Gilead announcement, they're not putting any name behind *THEIR* NIAID claim.

[uponit7771]

Be Careful of new Gilead announcement, they're not putting any name behind *THEIR* NIAID claim.

The news that just broke on Gilead broke minutes before the news on a greater decrease in GDP than market estimates

The news about the NIAID study came from no name just "... Gilead also said that a government-run clinical trial .." with no name behind it. The last time Gilead was pumped they didn't put a name behind the statements either.

I would love to know what the Gilead part of the statement means to the efficacy of the drug.

https://www.marketwatch.com/story/gileads-stock-halted-says-remdesivir-met-primary-endpoint-in-government-study-2020-04-29?mod=stocks

Gilead Sciences Inc. GILD, -1.53% on Wednesday morning announced data from two clinical trials testing its experimental drug remdesivir in severely ill COVID-19 patients. The drugmaker's stock was halted in premarket trading on Wednesday in advance of company disclosures about remdesivir's performance in the studies. Gilead said an open-label Phase 3 trial testing the therapy in severely ill patients found that those taking a 5-day or 10-day course of treatment led to similar results. At least 52% of participants taking either dosing regimen were discharged from the hospital after 14 days of treatment, and at least 53% of those patients were reported as reaching "clinical recovery." "Multiple concurrent studies are helping inform whether remdesivir is a safe and effective treatment for COVID-19," Gilead chief medical officer Merdad Parsey said in a statement. "The study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir." Minutes before this topline data was released, Gilead also said that a government-run clinical trial evaluating remdesivir in severely ill COVID-19 patients met the study's primary endpoint. That study is being conducted by the National Institute of Allergy and Infectious Diseases, which is expected to provide additional information about that trial, Gilead said. Gilead's stock has gained 21.0% year-to-date, while the S&P 500 SPX, 1.87% is down 11.3%.

[Mike 03]

1. Naturally, I hope there is some good news here

but I'm deeply unexcited and skeptical, and so far I haven't heard the doctors on "Doctor Radio" (SiriusXM) excited about it either. In fact, they were never excited about Remdesivir.

[uponit7771]

2. Is Doctors Radio talking about them now? The timing of the announcement is what got market watchers

... really pissed.

The 1Q GDP data is worse than expected and this data was given seconds after the data was released.

Trump mentioned this drug once, that itself makes me suspicious

[MineralMan]

3. Hey, Kids! Let's do the "Pump and Dump" Dance!

Whaddya say?

"There's a brand new dance
And it goes like this:

Chorus:
Pump and Dump - Pump and Dump

Hands in the air
Then drop to the floor.

Pump and Dump - Pump and Dump

Do it three times
Then come back for more.

Pump and Dump - Pump and Dump"

[Yonnie3]

4. No control group?

If there was no control group, this study merely indicates that a shorter treatment is as effective as a longer treatment. If the treatment is effective at all is left to other studies.

I seem to recall similar press for other illnesses with this drug and in the end no approvals.

[DrToast]

5. Two studies involved here

One study is testing the difference between 5-day and 10-day courses. No control group for that.

The NIAID study does have a control group and Gilead is saying that early results of study say Remdesivir has met the study's primary endpoint.

[Yonnie3]

6. Thanks

I looked harder and found the actual statement rather than the reporting: "Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational antiviral remdesivir for the treatment of COVID-19. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing."

I'll wait to see what the NIAID study actually says.

[uponit7771]

7. Does "met study's primary endpoint" mean anything? Looks like the 5 day vs 10 day means more ...

... supply of the IV drug.

[DrToast]

8. I think they would both be good news

If it met the study's primary endpoint, but that would usually mean it's more effective than a placebo.

The 5-day vs 10-day is good news because Remdesivir is difficult and time consuming to produce.

Here's what Gilead had previously estimated on availability:

-More than 140,000 treatment courses by the end of May 2020
-More than 500,000 treatment courses by October 2020
-More than 1 million treatment courses by December 2020
-Several million treatment courses in 2021, if required

Source: https://www.gilead.com/purpose/advancing-global-health/covid-19/working-to-supply-remdesivir-for-covid-19

This news would double those figures.

[Newest Reality]

9. That news...

That news, (despite other bad news) gave the stock market a 400-point erection today. Meanwhile states and municipalities are looking at letting a lot of people go.

Coincidence?

[uponit7771]

10. +1, and it look like Gilead did similar with this drug and Ebola. I'll wait for Fauci's take on this